The 2020 vancomycin monitoring guidelines were released in March during the COVID-19 pandemic response and therefore under the radar of many physicians.
They recommend a shift away from vancomycin trough levels to Area Under the Curve (AUC), in relation to the minimum inhibitory concentration (MIC) in adults, pediatrics, and neonates.
This dosing approach is recommended for patients with serious infections due to methicillin resistant Staphylococcus aureus (MRSA).
There are a number of studies demonstrating the clinical impact associated with inappropriate vancomycin dosing in many patients with MRSA infections utilizing trough levels alone, particularly ICU patients with renal insufficiency and obesity.
When vancomycin levels are suboptimal, treatment failures can occur due to isolates that have intermediate susceptibility to vancomycin or isolates that are resistant to vancomycin.
When dosing is too high, patients risk vancomycin-induced nephrotoxicity, which ranges from 5 to 43% with a relative risk of 2.45 (95% Confidence Interval: 1.69-3.55) based on clinical studies.
Vancomycin dosing based on AUC:MIC is now therefore recommended as the optimal dosing and monitoring method for the treatment of serious MRSA infections.
Dosing by AUC:MIC (as determined by broth microdilution) with a goal of 400-600 mg-hr/Liter should keep vancomycin concentration at therapeutic levels needed to achieve a clinical response, but below levels that might increase the risk of nephrotoxicity.
Methods of Calculating AUC:MIC
Bayesian Dosing Approach
Methods of calculating AUC include an equation-based methodology or a Bayesian approach, which utilizes population data to calculate a patient’s pharmacokinetics.
The Bayesian method, available through commercially available software programs, allows for precision dosing by creating an individualized, dynamic model of dosing vancomycin for every patient that can be updated over time as more patient specific information (e.g. vancomycin levels, serum creatinine) is received.
According to the new 2020 vancomycin dosing guidelines, the preferred approach to monitoring AUC is through these programs. This recommendation was given an A-III GRADE. Bayesian software programs can utilize drug levels obtained earlier in therapy (e.g. 24-48 hours) because it is not required that a patient’s vancomycin levels be stable, otherwise known as “steady state”. One recent study documented the transition from conventional trough-based vancomycin dosing to dosing based on two-point pharmacokinetics at four hospitals. Following the introduction of Bayesian dosing that targeted an AUC>400, patients had lower vancomycin troughs. Patients in the post-intervention group were more ill, however, there was no difference in nephrotoxicity between the two groups. Using a multivariable model, the use of two-point pharmacokinetics was associated with a reduction in nephrotoxicity.
First Order Kinetic Calculations
Another method that can be utilized to calculate AUC is by using “first order” kinetic calculations. Practically speaking, to make patient-specific adjustments to the vancomycin dose, two vancomycin levels within the same dosing interval are needed.
Unlike Bayesian dosing, this methodology requires patients to be at steady state when the levels are drawn.
The first level is obtained 1-2 hours after the end of the infusion (the peak) and the second level should be obtained prior to the next dose. With this information, a calculation can be made to adjust subsequent doses of vancomycin. Monitoring is recommended for patients with serious MRSA infections, but also all patients at high risk for nephrotoxicity (e.g., critically ill patients receiving concurrent nephrotoxic therapy), patients with unstable renal function, and those receiving prolonged courses of therapy (> 3 to 5 days).
Frequency of monitoring is based on clinical judgment but general recommendations are outlined:
- Early monitoring when doses exceed 2-3 grams per day in pediatric patients;
- Close monitoring in pediatric patients with poor or augmented renal function;
- Daily monitoring in hemodynamically unstable adults;
- Weekly monitoring in hemodynamically stable adults.
How can you prepare physicians for the conversion to AUC for vancomycin?
Educate Your Physicians
- It is important that all clinicians in your institution understand why and when this switch in dosing strategy will take place and to ensure that your pharmacists have been trained on this pharmacokinetic dosing strategy.
- Clinicians must expect vancomycin levels to be drawn more frequently in the first 24-48 hours of hospitalization to adjust the second dose of treatment.
- It will be especially important for Emergency Department clinicians, intensivists and hospitalists to understand this transition is happening, so they can facilitate vancomycin draws in the first 24-48 hours of hospitalization.
- Clinicians should not panic when concentration levels for vancomycin are lower than what is typically expected (e.g. 15mg/L or higher). It is not uncommon to see patients with a lower trough level who are still in the therapeutic AUC:MIC range.
- If not already in place at your institution, all clinicians should be in touch with pharmacists regarding all patients receiving vancomycin. Consider having discussions with pharmacy if clearance or the volume status of a patient changes significantly, perhaps requiring a recalculation of their vancomycin dosing.
Involve the Entire Care Team
- Nurses: Not only do physicians and other prescribers need to be educated about this new dosing strategy, but nurses must also be made aware so they understand they are no longer drawing trough levels but rather providing therapeutic drug monitoring that it somewhat less reliant on timing and frequency.
- Laboratory Staff: It is important to make laboratory staff and phlebotomists aware of these changes so they will run serum levels of vancomycin multiple times in the first few days of hospitalization. It is important that anyone drawing the vancomycin level document the exact time the level is being drawn as well as the dose of vancomycin at the time, in order for the AUC:MIC to be calculated accurately. Preparing hospital staff in advance of the change will prevent confusion when an inpatient requires vancomycin.
Review Patient Discharge Policies
- In order to ensure discharge and transitions of care are smooth for patients on vancomycin, it is important to find out how accepting facilities in your region such as subacute skilled nursing facilities, long-term acute care hospitals, and infusion centers are managing the guideline change.
- If there is advanced communication and preparation, it will save time at discharge and help facilitate discharge to one of these facilities or centers.
- The patient may be stable at discharge such that additional AUC:MIC do not have to be calculated.
- If the accepting facility does not dose to AUC, the discharge pharmacy team should consider transitioning back to traditional dosing strategies.
- It is important to enable the discharge team to spend adequate time outlining discharge dosing for vancomycin in order to ensure successful discharge. If patients are transitioning to home health, it is probably not reasonable to expect that home health agencies will be able to dose to AUC; the hospital pharmacy may give instructions to home health on monitoring weekly levels and dosing accordingly.
If physicians thoroughly understand the pharmacokinetic/pharmacodynamics behind the switch to AUC:MIC dosing, they may want to strongly reconsider if the patient requires vancomycin at all.
Hospital antibiotic stewardship programs should take this opportunity to focus on strategies to improve the use of this important Gram-positive agent and not reflexively place all critically ill patients on vancomycin for methicillin-resistant Staphylococcus aureus treatment.
Antibiotic Stewardship Committee meetings should dedicate time to educating themselves on this change and how it applies to their own institution, but then also develop a dedicated education strategy targeting hospital clinicians.
Stewards can emphasize how cumbersome the new dosing strategy will be to clinical pharmacists and how it may disrupt usual workflows as staff familiarize themselves with the new strategy.
Stewards can also emphasize the opportunity to improve the hospital’s utilization of vancomycin and consider if treatment is necessary at all, or to consider alternative treatment options such as linezolid, which is primarily metabolized in the liver.
In summary, hospitals should be preparing for this upcoming vancomycin dosing change. These are some activities physicians and pharmacy can engage in now:
- Educate clinicians focusing on Emergency Department physicians, intensivists, hospitalists and house staff on this change in practice
- Discuss with pharmacy what their strategy will be once the new dosing guidelines are released and whether clinical pharmacists have been adequately in serviced on how to calculate the AUC:MIC
- Educate hospital staff including nurses and laboratory personnel emphasizing the multiple draws in the first 24-48 hours of hospitalization and when there is a significant change in renal function or volumic status of the patient
- Discuss with regional accepting facilities and infusion centers how they are handling the change in guideline and agree on an approach to facilitate smooth transitions
- Ensure the hospital antibiotic stewardship program highlights vancomycin stewardship during this transition
Since the timing for these dosing changes are happening as we respond to COVID-19, it is important to have meetings on this change before and after implementation – to work out any glitches.
It is critical to work with your pharmacy closely to determine who can assist or carry out any of the tasks above, based on their comfort level with interacting with clinicians and regional facilities focused on the pandemic.
In antibiotic stewardship, we are rarely given an opportunity to improve use of an antibiotic across all US hospitals at once. Let’s take this opportunity to steward one of our most valuable therapeutic options – when hospitals will be re-evaluating their dosing strategy for vancomycin.
About the author
Dr. Trivedi has been an attending physician in the Emergency Room since 2010 and a Tele-Urgent Care physician since 2019 at the San Francisco Veterans’ Administration Medical Center. She has also been actively involved with the Society of Healthcare Epidemiology of America (SHEA) since 2010 and currently serves as a member of the Public Policy and Government Affairs Committee. She is the original Course Director for SHEA’s course Primer on Healthcare Epidemiology, Infection Control and Antimicrobial Stewardship: An Online Course for ID Fellows.
Since September 2014, she also functions as the Infection Control Committee Chair at Sutter Tracy Community Hospital. In February 2020, Dr. Trivedi joined the World Health Organization as a Consultant in the Antimicrobial Stewardship and Awareness Team in the Division of Antimicrobial Resistance.
Previously, Dr. Trivedi was the Public Health Medical Officer of the Healthcare Associated Infections Program at California Department of Public Health where she created, managed and led the California Antimicrobial Stewardship Program Initiative. Prior to CDPH, Dr. Trivedi served as an Epidemic Intelligence Service Officer in the United States Public Health Service with CDC’s Enteric Diseases Epidemiology Branch in Atlanta, Georgia.
Dr. Trivedi served on the antimicrobial resistance working group for the President’s Council of Advisors on Science and Technology. She is the author of many publications related to limiting antimicrobial resistance, promoting antimicrobial stewardship and improving infection control practices. Most recently she was an editor for the 1st edition of the SHEA text Practical Implementation of an Antibiotic Stewardship Program.
Dr. Trivedi received her medical degree from Stanford University School of Medicine and completed residency in Internal Medicine at the University of California, San Francisco. She is board certified in Internal Medicine.
- Neely MN, Kato L, Youn G et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018; 62(2):e02042-17.
- Choi YC, Saw S, Soliman D et al. Intravenous vancomycin associated with the development of nephrotoxicity in patients with class III obesity. Ann Pharmacother. 2017; 51(11):937-944.
- Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52(4):1330-1336.
- Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013; 57(2):734-744.
- Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016; 11(12):2132-2140.
- The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1979; 121(9):1193-1254.
- Finch N, Zasowski E, Murray K, et al. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12).